Phase 1/2 × Carcinoma, Ovarian Epithelial × pembrolizumab × Clear all
NCT05086692 2025-07-09

ABILITY-1

Medicenna Therapeutics, Inc.

Phase 1/2 Recruiting
115 enrolled
NCT05620134 2024-10-15

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Salubris Biotherapeutics Inc

Phase 1/2 Active not recruiting
263 enrolled